Neoadjuvant therapy with tyrosine kinase inhibitors has been proposed as a feasible approach for downstaging potential resectable non-small cell lung cancer (NSCLC). Pralsetinib is a paradigm of precision medicine for cancers driven by mutant RET (rearranged d... ...

请注册登录后继续浏览